Stoiukhina A S, Chesalin I P
Vestn Oftalmol. 2014 Jul-Aug;130(4):39-44.
Choosing the treatment method for patients with large choroidal melanomas remains a subject of debate. No literature data can be found on survival of such patients after either eye-preserving surgery or enucleation that takes into account the initial tumor size. The purpose of the study was to analyze the five-year survival rates for large choroidal melanomas (by J.A. Shields) in respect of the provided treatment.
Medical records of 103 patients who had undergone treatment for choroidal melanoma (initial prominence 5.0-10.2 mm, initial diameter 7.3-20 mm) were studied. Eye-preserving surgery was performed on 60 patients, of whom 46 patients received brachytherapy (single session in 37 cases) and the other 14 patients--brachytherapy in combination with transpupillary thermotherapy (with subsequent endoresection of the tumor in one case). A total of 16 patients from this group required secondary enucleation. Primary enucleation was performed on 63 patients. Histopathological results confirming choroidal melanoma were analyzed in all 79 cases.
The 5-year melanoma-specific cumulative survival rate in the group of eye-preserving surgery was 0.8146, while in the group of primary enucleation it reached 0.8951. The 8-year rate was 0.6921 and 0.7558 correspondingly. However, according to Gehan-Wilcoxon test, the differences were statistically insignificant (p = 0.11). The five-year survival of large choroidal melanoma patients who underwent eye-preserving surgery and no enucleation was 0.7708, 9-year - 0.6175.
Since the five-year melanoma-specific survival rate after primary enucleation is higher than that after eye-preserving surgery and secondary enucleation (though the difference is statistically insignificant), treatment options for large choroidal melanomas have to be chosen individually, taking into account the age and attitude of the patient as well as the size of the tumor.
对于患有大脉络膜黑色素瘤的患者,选择治疗方法仍然是一个有争议的话题。在考虑初始肿瘤大小的情况下,无论是保眼手术还是眼球摘除术后此类患者的生存率,均未找到相关文献数据。本研究的目的是分析大脉络膜黑色素瘤(根据J.A. 希尔兹分类)在接受特定治疗后的五年生存率。
研究了103例接受脉络膜黑色素瘤治疗患者的病历(初始隆起度5.0 - 10.2毫米,初始直径7.3 - 20毫米)。60例患者接受了保眼手术,其中46例患者接受了近距离放射治疗(37例为单次治疗),另外14例患者接受了近距离放射治疗联合经瞳孔温热疗法(其中1例随后进行了肿瘤内切除术)。该组共有16例患者需要二次眼球摘除术。63例患者接受了一期眼球摘除术。对所有79例病例的组织病理学结果进行分析,以确诊脉络膜黑色素瘤。
保眼手术组黑色素瘤特异性五年累积生存率为0.8146,而一期眼球摘除术组则达到0.8951。八年生存率分别为0.6921和0.7558。然而,根据Gehan - Wilcoxon检验,差异无统计学意义(p = 0.11)。接受保眼手术且未进行眼球摘除术的大脉络膜黑色素瘤患者五年生存率为0.7708,九年生存率为0.6175。
由于一期眼球摘除术后黑色素瘤特异性五年生存率高于保眼手术和二次眼球摘除术后(尽管差异无统计学意义),对于大脉络膜黑色素瘤的治疗方案必须根据患者的年龄、意愿以及肿瘤大小进行个体化选择。